---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-026736"
form_type: "8-K"
ticker: "ASMB"
cik: "0001426800"
company_name: "ASSEMBLY BIOSCIENCES, INC."
filed_at: "2022-12-19T23:59:59+00:00"
generated_at: "2026-06-21T02:26:53.142236+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Assembly Biosciences reports promising interim results for HBV core inhibitors 3733 and 4334

## Summary
- ABI-H3733 50 mg cohort: 6 of 8 HBV patients reached HBV DNA <LLOQ by day 21; mean 3.1 log decline.
- No serious adverse events or significant ALT elevations observed in either study.
- ABI-4334 30 mg single-dose showed 24-hour half-life supporting once-daily oral dosing; PK suggests high potency.
- 100 mg cohorts ongoing for both studies; further data expected in Q1 2023.
- ABI-H3733 25 mg cohort enrolled; initial 5 patients showed mean HBV DNA reduction of ~1.9 logs.

## SEC filing metadata
- accession: 0000950170-22-026736
- form_type: 8-K
- ticker: ASMB
- cik: 0001426800
- company_name: ASSEMBLY BIOSCIENCES, INC.
- filed_at: 2022-12-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1426800/000095017022026736/0000950170-22-026736-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1426800/000095017022026736/asmb-20221219.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-026736
- JSON: https://secwatch.observer/filing/0000950170-22-026736.json
- Plain text: https://secwatch.observer/filing/0000950170-22-026736.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.